论文信息 - Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. - 字舞流文

Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.

M. Fakih | B. Carneiro | B. Lembersky | N. Bahary | S. Krishnamurthi | R. Stoller | R. Ramanathan | D. Potter | A. Schmotzer | R. Pinkerton | T. Crandall | S. Lancaster